Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.51 |
| ▸ | ACACB | O00763 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 3/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30888835 | 0.80 | P2RY12 (0.48) | HSD17B10TSHRP2RY12USP2 | |
| SCHEMBL17626880 | 0.79 | HRH3 (0.60) | OGAACACBMAP4K4 | |
| SCHEMBL17626627 | 0.79 | HRH3 (0.60) | OGAACACBMAP4K4 | |
| SCHEMBL18691293 | 0.79 | HRH3 (0.60) | OGAACACBMAP4K4 | |
| SCHEMBL24891365 | 0.77 | P2RY12 (0.46) | ALDH1A1HSD17B10TSHRP2RY12USP2 | |
| SCHEMBL2921143 | 0.77 | P2RY12 (0.59) | ALDH1A1TSHRP2RY12USP2 | |
| SCHEMBL29521457 | 0.77 | P2RY12 (0.59) | ALDH1A1TSHRP2RY12USP2 | |
| SCHEMBL3059830 | 0.77 | P2RY12 (0.59) | ALDH1A1TSHRP2RY12USP2 | |
| SCHEMBL29868881 | 0.76 | HRH3 (0.49) | ALDH1A1HSD17B10TSHR | |
| SCHEMBL29373138 | 0.76 | HRH3 (0.49) | ALDH1A1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255987-A1 | AQUEOUS PHARMACEUTICAL COMPOSITION COMPRISING A P2Y12 RECEPTOR ANTAGONIST | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255987-A1 | AQUEOUS PHARMACEUTICAL COMPOSITION COMPRISING A P2Y12 RECEPTOR ANTAGONIST | P2RY12, P2RY11, P2RY1 | OGA 4355/4885ACACB 4195/4885ALDH1A1 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.